NCT02388295 - AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

September 19, 2016

Study Completion Date

September 19, 2016

Conditions

Multiple System Atrophy, MSA

Interventions

DRUG

AZD3241

Drug: AZD3241 administered for 12 weeks orally as a tablet.

DRUG

Placebo

Placebo to match AZD3241 administered for 12 weeks orally as a tablet.

Trial Locations (17)

6020

Research Site, Innsbruck

10016

Research Site, New York

10032

Research Site, New York

20520

Research Site, Turku

31059

Research Site, Toulouse

33076

Research Site, Bordeaux

33613

Research Site, Tampa

55905

Research Site, Rochester

84131

Research Site, Salerno

94305

Research Site, Stanford

06520-8048

Research Site, New Haven

02215

Research Site, Boston

48105-2945

Research Site, Ann Arbor

141 86

Research Site, Stockholm

SE5 9RJ

Research Site, London

W12 0NN

Research Site, London

OX3 9DU

Research Site, Oxford